Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Breast Cancer

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 30 articles: HTML format

Single Articles

July 2022
1. PIVOT X
   Pembrolizumab in the Treatment of Breast Cancer.
   N Engl J Med. 2022;387:273-274.
   PubMed    
   
   
   
2. CORTES J, Rugo HS, Cescon DW, Im SA, et al
   Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
   N Engl J Med. 2022;387:217-226.
   PubMed     Abstract available
   
   
   
3. HURVITZ SA
   DESTINY-Changing Results for Advanced Breast Cancer.
   N Engl J Med. 2022;387:75-76.
   PubMed    
   
   
   June 2022
4. JATOI I, Sung H, Jemal A
   The Emergence of the Racial Disparity in U.S. Breast-Cancer Mortality.
   N Engl J Med. 2022;386:2349-2352.
   PubMed    
   
   
   
5. CORTES J, Im SA, Cathcart J
   Trastuzumab Deruxtecan for Breast Cancer. Reply.
   N Engl J Med. 2022;386:2347.
   PubMed    
   
   
   
6. ZHENG F, Du F, Yuan P
   Trastuzumab Deruxtecan for Breast Cancer.
   N Engl J Med. 2022;386:2346-2347.
   PubMed    
   
   
   
7. MODI S, Jacot W, Yamashita T, Sohn J, et al
   Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
   N Engl J Med. 2022 Jun 5. doi: 10.1056/NEJMoa2203690.
   PubMed     Abstract available
   
   
   May 2022
8. SCHMID P, Cortes J, Dent R
   Pembrolizumab in Early Triple-Negative Breast Cancer. Reply.
   N Engl J Med. 2022;386:1771-1772.
   PubMed    
   
   
   
9. GANGULY S, Gogia A
   Pembrolizumab in Early Triple-Negative Breast Cancer.
   N Engl J Med. 2022;386:1771.
   PubMed    
   
   
   March 2022
10. CORTES J, Kim SB, Chung WP, Im SA, et al
    Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
    N Engl J Med. 2022;386:1143-1154.
    PubMed     Abstract available
    
    
    
11. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
    N Engl J Med. 2022;386:942-950.
    PubMed     Abstract available
    
    
    February 2022
12. SCHMID P, Cortes J, Dent R, Pusztai L, et al
    Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
    N Engl J Med. 2022;386:556-567.
    PubMed     Abstract available
    
    
    December 2021
13. SHARMA V, Kumar A
    Carcinoma en Cuirasse.
    N Engl J Med. 2021;385:2562.
    PubMed    
    
    
    
14. KALINSKY K, Barlow WE, Gralow JR, Meric-Bernstam F, et al
    21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
    N Engl J Med. 2021;385:2336-2347.
    PubMed     Abstract available
    
    
    October 2021
15. TUTT ANJ, Garber JE, Geyer CE Jr
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer. Reply.
    N Engl J Med. 2021;385:1440.
    PubMed    
    
    
    
16. HOSHI A, Bando H, Sekine I
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    N Engl J Med. 2021;385:1439-1440.
    PubMed    
    
    
    
17. NOZAWA K, Yoshimura A, Iwata H
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    N Engl J Med. 2021;385:1439.
    PubMed    
    
    
    September 2021
18. BOSE R, Ma CX
    Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance.
    N Engl J Med. 2021;385:1241-1243.
    PubMed    
    
    
    July 2021
19. GOODWIN PJ
    Extended Aromatase Inhibitors in Hormone-Receptor-Positive Breast Cancer.
    N Engl J Med. 2021;385:462-463.
    PubMed    
    
    
    
20. GNANT M, Fitzal F, Rinnerthaler G, Steger GG, et al
    Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
    N Engl J Med. 2021;385:395-405.
    PubMed     Abstract available
    
    
    
21. BARDIA A, Hurvitz SA, Rugo HS
    Sacituzumab Govitecan in Metastatic Breast Cancer. Reply.
    N Engl J Med. 2021;385:e12.
    PubMed    
    
    
    
22. GANGULY S, Gogia A
    Sacituzumab Govitecan in Metastatic Breast Cancer.
    N Engl J Med. 2021;385:e12.
    PubMed    
    
    
    June 2021
23. TUTT ANJ, Garber JE, Kaufman B, Viale G, et al
    Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
    N Engl J Med. 2021 Jun 3. doi: 10.1056/NEJMoa2105215.
    PubMed     Abstract available
    
    
    April 2021
24. BARDIA A, Hurvitz SA, Tolaney SM, Loirat D, et al
    Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
    N Engl J Med. 2021;384:1529-1541.
    PubMed     Abstract available
    
    
    March 2021
25. BURSTEIN HJ
    Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Reply.
    N Engl J Med. 2021;384:1176-1177.
    PubMed    
    
    
    
26. COPUR MS
    Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    N Engl J Med. 2021;384:1176.
    PubMed    
    
    
    January 2021
27. DORLING L, Carvalho S, Allen J, Gonzalez-Neira A, et al
    Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.
    N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMoa1913948.
    PubMed     Abstract available
    
    
    
28. NAROD SA
    Which Genes for Hereditary Breast Cancer?
    N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMe2035083.
    PubMed    
    
    
    
29. HU C, Hart SN, Gnanaolivu R, Huang H, et al
    A Population-Based Study of Genes Previously Implicated in Breast Cancer.
    N Engl J Med. 2021 Jan 20. doi: 10.1056/NEJMoa2005936.
    PubMed     Abstract available
    
    
    December 2020
30. BURSTEIN HJ
    Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    N Engl J Med. 2020;383:2557-2570.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: